Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Cash And Cash Equivalents : $9,330 Mil (As of Mar. 2024)

View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co Cash And Cash Equivalents?

Bristol-Myers Squibb Co's quarterly cash and cash equivalents increased from Sep. 2023 ($7,514.00 Mil) to Dec. 2023 ($11,464.00 Mil) but then stayed the same from Dec. 2023 ($11,464.00 Mil) to Mar. 2024 ($9,330.00 Mil).

Bristol-Myers Squibb Co's annual cash and cash equivalents declined from Dec. 2021 ($13,979.00 Mil) to Dec. 2022 ($9,123.00 Mil) but then increased from Dec. 2022 ($9,123.00 Mil) to Dec. 2023 ($11,464.00 Mil).

Bristol-Myers Squibb Co Cash And Cash Equivalents Historical Data

The historical data trend for Bristol-Myers Squibb Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Cash And Cash Equivalents Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

12,346.00

14,546.00

13,979.00

9,123.00

11,464.00

Bristol-Myers Squibb Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															8,995.00	8,372.00	7,514.00	11,464.00	9,330.00

Bristol-Myers Squibb Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Bristol-Myers Squibb Co (NYSE:BMY) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Bristol-Myers Squibb Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Executives

Christopher S. Boerner	officer: EVP, Chief Commercial Officer	21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii	director	1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman	officer: EVP, Corporate Affairs	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge	officer: SVP, Human Resources	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge	officer: EVP, Chief Research Officer	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey	officer: Pres., Research & Early Dev.	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky	officer: EVP, Chief Commercial Officer	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio	officer: EVP & Chief Commercial Officer	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins	officer: EVP, Chief Financial Officer	C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt	director	BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung	officer: Vice President and Secretary	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees	officer: SVP & Controller	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan	officer: EVP, Glob. Prod. Dev. & Supply	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers	officer: EVP, Chief Digital & Tech Off.	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von	officer: SVP, Enterp. Services & CIO	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543